
GUTS Stock Forecast & Price Target
GUTS Analyst Ratings
Bulls say
Fractyl Health is well-positioned for success with their novel approach to treating obesity and type 2 diabetes, demonstrated by positive clinical trial results for their lead product candidate Revita and the recent authorization for a clinical trial for their gene therapy candidate. They are also benefiting from the new RAPID pathway for medical device coverage, which could shorten reimbursement timelines and increase market access. With plans for regulatory milestones and a strong financial outlook, Fractyl is a promising investment opportunity for those with a positive outlook on their innovative therapies for metabolic disease.
Bears say
Fractyl Health is facing potential risks with their lead product candidate Revita, as data shows a high rate of weight regain in patients after discontinuing treatment with similar GLP-1 drugs. While the company has received FDA breakthrough designation and is targeting Medicare beneficiaries for faster coverage and adoption, the requirement for patients to maintain a 5% weight loss may pose a challenge given the observed weight regain rate. Additionally, the company's YE26 price target of $8 per share is based on an aggressive sum-of-the-parts peak revenue analysis with high multiples.
This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GUTS Analyst Forecast & Price Prediction
Start investing in GUTS
Order type
Buy in
Order amount
Est. shares
0 shares